|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
|
30887605 |
2019 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Very recently, erdafitinib, a pan-FGFR inhibitor, has been granted accelerated approval by FDA for platinum-pretreated advanced metastatic UC with susceptible FGFR3 or FGFR2 genetic alterations.
|
31030123 |
2019 |
|
Carcinoma, Transitional Cell
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we report several key insights from our molecular dissection of this disease: 1) Most UTUCs are luminal-papillary; 2) UTUC has a T-cell depleted immune contexture; 3) High FGFR3 expression is enriched in UTUC and correlates with its T-cell depleted immune microenvironment; 4) Sporadic UTUC is characterized by a lower total mutational burden than urothelial carcinoma of the bladder.
|
31278255 |
2019 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations of fibroblast growth factor receptor 3 (FGFR3) are common in urothelial carcinoma of the bladder (UC).
|
30952872 |
2019 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
The frequency of FGFR3 aberrations was higher in bladder UC (25%) than in UC of the renal pelvis and ureter (18%) but the difference was not statistically significant (P = 0.444).
|
30064409 |
2018 |
|
Carcinoma, Transitional Cell
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The differential expression levels of FGFR3-AS1 and FGFR3 in tumor tissues and paired normal tissues were determined using Real-Time qPCR in a total of 36 patients diagnosed with bladder cancer (urothelial carcinoma).
|
29226855 |
2018 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
Absent clinical activity suggests that patient selection by pFGFR3 IHC alone does not enrich for response to FGFR3 kinase inhibitors in urothelial carcinoma.<i></i>.
|
27932416 |
2017 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
We argue that routine use of molecular genomic tumour analysis in UC may inform selection of patients for appropriate trials and we further investigate the potential of FGFR3 as a meaningful clinical target for this difficult disease.
|
27271022 |
2016 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to analyze the frequency and association of FGFR3 and RAS gene mutations in UC cases.
|
27356691 |
2016 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGFR3 immunohistochemistry staining is present in one third of primary muscle-invasive UCs and half of metastases, while FGFR3 mutations and copy number changes are relatively uncommon.
|
24846059 |
2014 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alterations in fibroblast growth factor receptor 3 (FGFR3) have been implicated in the pathogenesis of urothelial carcinoma.
|
24360661 |
2014 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this review, we discuss the biologic and prognostic impact of FGFR3 mutations in UC as well as FGFR3 as a potential target for novel therapeutics.
|
22285006 |
2013 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
CTD_human |
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation.
|
24121792 |
2013 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We determined whether FGFR3 mutation analysis of voided urine samples would be cost-effective to partly replace cystoscopy in the surveillance of patients treated for nonmuscle invasive urothelial carcinoma.
|
23142690 |
2013 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in FGFR3 are known to be associated with urothelial carcinoma and have a positive predictive value of 95% when detected in patients with no history of TCC.
|
22873290 |
2012 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
• Paraffin-embedded transurethral resection tissue from 113 patients with UC was investigated for the association of p85aPI3K, p-AKT, p-mTOR, p-p70S6K and p-4E-BP1 (eukaryotic initiation factor 4E-binding protein 1) expression status, as well as PIK3CA and AKT1 mutations with p-extracellular signal-regulated kinase 1/2 (ERK1/2), fibroblast growth factor receptor 3 (FGFR3), pathological features, recurrence and cancer-specific survival.
|
23107319 |
2012 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Somatic point mutations in the fibroblast growth factor receptor 3 (FGFR3) gene have been identified in certain types of urological cancers, especially urothelial carcinoma of the bladder and the renal pelvis, and could be correlated with a favourable outcome.
|
22203473 |
2012 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 appears to be the most frequently mutated oncogene in transitional cell carcinoma; its mutation is strongly associated with low tumor grade, early stage, and low recurrence rate, which confer a better overall prognosis.
|
21106220 |
2011 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that inhibition of FGFR1 and wild-type or mutant FGFR3 may represent a useful therapeutic approach in patients with both non-muscle invasive and muscle invasive UC.
|
21119661 |
2011 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Several downstream targets of FGFR3 are also mutated in UC, e.g., PIK3CA, AKT1, and RAS.
|
21533174 |
2011 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.
|
21547910 |
2011 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
|
19621447 |
2009 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 is frequently activated by mutation in urothelial carcinoma (UC) and represents a potential target for therapy.
|
17668422 |
2007 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Somatic FGFR3 mutations have been reported in various cancers such as urothelial carcinoma.
|
17568799 |
2007 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, the same FGFR3 mutations known from skeletal dysplasia syndromes and urothelial carcinoma have been shown to cause benign human skin tumors such as seborrheic keratoses and epidermal nevi.
|
17172848 |
2006 |